EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
Authors:
- Giovanna FinocchiaroGFGiovanna Finocchiaro
- Luca ToschiLTLuca Toschi
- Isabella GarassinoIGIsabella Garassino
- Fabio De VincenzoFVFabio De Vincenzo
- Elisabetta CampagnoliECElisabetta Campagnoli
- Paolo ZucaliPZPaolo Zucali
- Raffaele CavinaRCRaffaele Cavina
- Giovanni L CeresoliGCGiovanni L Ceresoli
- Armando SantoroASArmando Santoro
- Federico CappuzzoFCFederico Cappuzzo
- 23 October 2007
- journal article
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 1 (2) , 183-191
Abstract
The EGF receptor (EGFR) is one of the most important targets for cancer treatment implicated in the control of cell survival, proliferation and metastasis. In the last few years different EGFR molecular antagonists have been evaluated in the clinical setting and some of these drugs have demonstrated clinical efficacy in a subset of non-small cell lung cancer (NSCLC) patients. Gefitinib or erlotinib are a new class of compounds able to inhibit the tyrosine kinase domain of EGFR (EGFR TKI) and, during recent years, clinical and biologic predictors for TKI sensitivity have been identified. Among clinical features, never-smoking history has emerged as the most relevant clinical characteristic predictive of response to TKIs in NSCLC, and EGFR gene mutation or EGFR increased gene copy number represent critical biologic variables associated with an improved outcome for patients exposed to these agents. Unfortunately, cancer cells possess escape mechanisms to overcome inhibition of cell proliferation leading to drug resistance. There are several mechanisms that have been identified as responsible for intrinsic or acquired resistance. The aim of the present review is to analyze available data in order to identify an optimal paradigm for patient selection.Keywords
This publication has 74 references indexed in Scilit:
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Biologically Targeted Treatment of Non–Small-Cell Lung Cancer: Focus on Epidermal Growth Factor ReceptorClinical Lung Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal growth factor receptor expression, signal pathway, and inhibitors in non[ndash ]small cell lung cancerSeminars in Oncology, 2002